Biologics, Inc. (NC) Selected by Genentech as Strategic Partner for Launch of New Targeted Oral Oncology Therapy

CARY, N.C.--(BUSINESS WIRE)--Biologics, Inc., an integrated oncology management company, announces today that it has been selected by Genentech, a member of the Roche Group, as the strategic partner to support their suite of services for Zelboraf® (vemurafenib). Zelboraf was approved by the FDA on August 17 as a new oral therapy for the treatment of patients with unresectable or metastatic melanoma with BRAFV600E mutation as detected by an FDA-approved test. In collaboration with Genentech, Biologics is a key provider of patient access, clinical support and pharmacy services for Zelboraf patients.